Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 120802, 15 pages
http://dx.doi.org/10.1155/2015/120802
Research Article

Application of Molecular Modeling to Development of New Factor Xa Inhibitors

1Research Computer Center, Moscow State University, Leninskie Gory 1, Building 4, Moscow 119991, Russia
2Dimonta, Ltd., Nagornaya Street 15, Building 8, Moscow 117186, Russia
3Laboratory of Physical Biochemistry, National Research Center for Hematology, Russian Academy of Medical Sciences, Novyi Zykovskiy Proezd, 4a, Moscow 125167, Russia
4Laboratory of Biophysics and Physiology of Cell, Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Kosygin Street, 4, Moscow 119991, Russia
5Faculty of Chemistry, Moscow State University, Leninskie Gory 1, Building 3, Moscow 119991, Russia
6Faculty of Chemistry, Voronezh State University, Universitetskaya Plóshchaď 1, Voronezh 394006, Russia
7Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Samory Mashela Street 1, Moscow 117198, Russia
8Faculty of Physics, Moscow State University, Leninskie Gory 1, Building 2, Moscow 119991, Russia

Received 16 April 2015; Revised 12 August 2015; Accepted 20 August 2015

Academic Editor: Alfonso T. García-Sosa

Copyright © 2015 Vladimir B. Sulimov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Matter, E. Defossa, U. Heinelt et al., “Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa,” Journal of Medicinal Chemistry, vol. 45, no. 13, pp. 2749–2769, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Ostrovsky, M. Udier-Blagović, and W. L. Jorgensen, “Analyses of activity for factor Xa inhibitors based on Monte Carlo simulations,” Journal of Medicinal Chemistry, vol. 46, no. 26, pp. 5691–5699, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. A. G. G. Turpie, “Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1238–1247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Hermans and D. Claeys, “Review of the rebound phenomenon in new anticoagulant treatments,” Current Medical Research and Opinion, vol. 22, no. 3, pp. 471–481, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. K. G. Mann, K. Brummel, and S. Butenas, “What is all that thrombin for?” Journal of Thrombosis and Haemostasis, vol. 1, no. 7, pp. 1504–1514, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Walenga, W. P. Jeske, D. Hoppensteadt, and J. Fareed, “Factor Xa inhibitors: today and beyond,” Current Opinion in Investigational Drugs, vol. 4, no. 3, pp. 272–281, 2003. View at Google Scholar · View at Scopus
  7. A. Lindström, L. Edvinsson, A. Johansson et al., “Postprocessing of docked protein-ligand complexes using implicit solvation models,” Journal of Chemical Information and Modeling, vol. 51, no. 2, pp. 267–282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. A. Bauer, “New anticoagulants: anti IIa vs anti Xa—is one better?” Journal of Thrombosis and Thrombolysis, vol. 21, no. 1, pp. 67–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. K. R. Guertin and Y.-M. Choi, “The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development,” Current Medicinal Chemistry, vol. 14, no. 23, pp. 2471–2481, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. I. Eriksson, A. G. G. Turpie, M. R. Lassen et al., “A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery,” Journal of Thrombosis and Haemostasis, vol. 5, no. 8, pp. 1660–1665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. B. I. Eriksson, D. J. Quinlan, and J. I. Weitz, “Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development,” Clinical Pharmacokinetics, vol. 48, no. 1, pp. 1–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Abdulsattar, R. Bhambri, and A. Nogid, “Rivaroxaban (Xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor Xa inhibitor,” P & T, vol. 34, no. 5, pp. 238–244, 2009. View at Google Scholar · View at Scopus
  13. C. Frost, J. Wang, S. Nepal et al., “Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects,” British Journal of Clinical Pharmacology, vol. 75, no. 2, pp. 476–487, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Furugohri, K. Isobe, Y. Honda et al., “DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles,” Journal of Thrombosis and Haemostasis, vol. 6, no. 9, pp. 1542–1549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. P. Pinto, J. M. Smallheer, D. L. Cheney, R. M. Knabb, and R. R. Wexler, “Factor Xa inhibitors: next-generation antithrombotic agents,” Journal of Medicinal Chemistry, vol. 53, no. 17, pp. 6243–6274, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Nazaré, D. W. Will, H. Matter et al., “Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography,” Journal of Medicinal Chemistry, vol. 48, no. 14, pp. 4511–4525, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. N. Romanov, O. A. Kondakova, F. V. Grigoriev et al., “The SOL docking package for computer-aided drug design,” Numerical Methods, vol. 9, no. 2, pp. 213–233, 2008 (Russian). View at Google Scholar
  18. I. V. Oferkin, A. V. Sulimov, O. A. Kondakova, and V. B. Sulimov, “Implementation of parallel computing for docking programs SOLGRID and SOL,” Numerical Methods, vol. 12, no. 1, pp. 205–219, 2011 (Russian). View at Google Scholar
  19. A. V. Sulimov, D. C. Kutov, I. V. Oferkin, E. V. Katkova, and V. B. Sulimov, “Application of the docking program SOL for CSAR benchmark,” Journal of Chemical Information and Modeling, vol. 53, no. 8, pp. 1946–1956, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. V. Finkelstein and O. B. Ptitsyn, Protein Physics, Knizhnyi Dom Universitet, Moscow, Russia, 2005.
  21. M. Böhm, J. Stürzebecher, and G. Klebe, “Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa,” Journal of Medicinal Chemistry, vol. 42, no. 3, pp. 458–477, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. S. S. Bhunia, K. K. Roy, and A. K. Saxena, “Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches,” Journal of Chemical Information and Modeling, vol. 51, no. 8, pp. 1966–1985, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Sagi, T. Nakagawa, M. Yamanashi et al., “Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids,” Journal of Medicinal Chemistry, vol. 46, no. 10, pp. 1845–1857, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Senger, M. A. Convery, C. Chan, and N. S. Watson, “Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 22, pp. 5731–5735, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. H. G. Wallnoefer, K. R. Liedl, and T. Fox, “A GRID-derived water network stabilizes molecular dynamics computer simulations of a protease,” Journal of Chemical Information and Modeling, vol. 51, no. 11, pp. 2860–2867, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. The Protein Data Bank, http://www.rcsb.org/.
  27. APLITE Program, Dimonta, http://dimonta2.1gb.ru/en/node/55.
  28. T. A. Halgren, “Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94,” Journal of Computational Chemistry, vol. 17, no. 5-6, pp. 490–519, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. R. A. Laskowski, J. A. C. Rullmann, M. W. MacArthur, R. Kaptein, and J. M. Thornton, “AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR,” Journal of Biomolecular NMR, vol. 8, no. 4, pp. 477–486, 1996. View at Google Scholar · View at Scopus
  30. The validation of SOL docking program, http://www.keenbase.ru/en/index.htm.
  31. G. M. Morris, D. S. Goodsell, R. S. Halliday et al., “Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function,” Journal of Computational Chemistry, vol. 19, no. 14, pp. 1639–1662, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. A. N. Romanov, S. N. Jabin, Y. B. Martynov, A. V. Sulimov, F. V. Grigoriev, and V. B. Sulimov, “Surface generalized born method: a simple, fast, and precise implicit solvent model beyond the coulomb approximation,” The Journal of Physical Chemistry A, vol. 108, no. 43, pp. 9323–9327, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. E. I. Sinauridze, A. N. Romanov, I. V. Gribkova et al., “New synthetic thrombin inhibitors: molecular design and experimental verification,” PLoS ONE, vol. 6, no. 5, Article ID e19969, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. V. B. Sulimov, E. V. Katkova, I. V. Oferkin et al., “Application of molecular modeling to urokinase inhibitors development,” BioMed Research International, vol. 2014, Article ID 625176, 15 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Künzel, A. Schweinitz, S. Reißmann, J. Stürzebecher, and T. Steinmetzer, “4-Amidinobenzylamine-based inhibitors of urokinase,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 4, pp. 645–648, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. J. R. Spencer, D. McGee, D. Allen et al., “4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 15, pp. 2023–2026, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. D.-M. Feng, S. J. Gardell, S. D. Lewis et al., “Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position,” Journal of Medicinal Chemistry, vol. 40, no. 23, pp. 3726–3733, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Stürzebecher, D. Prasa, J. Hauptmann, H. Vieweg, and P. Wikström, “Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine,” Journal of Medicinal Chemistry, vol. 40, no. 19, pp. 3091–3099, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Schweinitz, T. Steinmetzer, I. J. Banke et al., “Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents,” The Journal of Biological Chemistry, vol. 279, no. 32, pp. 33613–33622, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. ChemAxon, http://www.chemaxon.com/.
  41. J. Nocedal and S. J. Wright, Numerical Optimization, Springer Science+Business Media, New York, NY, USA, 2006.
  42. O. Y. Kupervasser, S. N. Zhabin, Y. B. Martynov et al., “Continual model of solvent: the DISOLV software—algorithms, implementation, and validation,” Numerical Methods, vol. 12, pp. 246–261, 2011 (Russian). View at Google Scholar
  43. V. B. Sulimov, E. V. Katkova, I. V. Oferkin, and M. P. Kochugaeva, “PCM, COSMO, and surface GB implementation in program DISOLV: development and validation,” in Proceedings of the 244th ACS National Meeting, Oral presentation COMP 441, Philadelphia, Pa, USA, August 2012.
  44. S. M. Schwarzl, Th. B. Tschopp, J. C. Smith, and S. Fischer, “Can the calculation of ligand binding free energies be improved with continuum solvent electrostatics and an ideal-gas entropy correction?” Journal of Computational Chemistry, vol. 23, no. 12, pp. 1143–1149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. NCI Diversity Set, http://dtp.cancer.gov/branches/dscb/diversity_explanation.html.
  46. The Open Babel Package, Version 2.3.1, http://openbabel.org/.
  47. Y. A. Ivanov, N. L. Zaichenko, S. V. Rykov et al., “The synthesis of hydroxy, acyloxy, oxo, N-oxide oxo, and morpholino derivatives of hydrogenated quinolines and study of their radical analogs by ESR,” Bulletin of the Academy of Sciences of the USSR Division of Chemical Science, vol. 28, no. 8, pp. 1661–1668, 1979. View at Publisher · View at Google Scholar · View at Scopus
  48. S. M. Medvedeva, K. S. Shikhaliev, and Z. V. Shmyreva, “Some transformations of 6-oxy-2,2,4-trimethyl-1,2-dihydroquinoline,” Problemy Khimii i Biologii, vol. 1, no. 1, pp. 38–40, 2002. View at Google Scholar
  49. E. V. Leshhyeva, S. M. Medvedeva, and K. S. Shikhaliev, “Synthesis of 4,4,6-trimethyl-8-4H-pirrolo[3,2,1-IJ]quinolin-1,2-diones,” Zhurnal Organichnoii ta Farmacevtichnoii Khimii, vol. 2, no. 46, pp. 15–20, 2014. View at Google Scholar
  50. E. V. Leshhyeva, K. S. Shikhaliev, and G. V. Satalov, “Synthesis of functional derivatives of 4,4,6-trimethyll-4n-pirrolo[3,2,1-ij] quinolin-1,2-diones,” Vestnik Voronezhskogo Gosudarstvennogo Universiteta. Problemy Khimii i Biologii, vol. 1, no. 1, pp. 34–37, 2002. View at Google Scholar
  51. A. E. Klon, M. Glick, M. Thoma, P. Acklin, and J. W. Davies, “Finding more needles in the haystack: a simple and efficient method for improving high-throughput docking results,” Journal of Medicinal Chemistry, vol. 47, no. 11, pp. 2743–2749, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Shi, C. Li, S. P. O'Connor et al., “Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 24, pp. 6882–6889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Volkamer, A. Griewel, T. Grombacher, and M. Rarey, “Analyzing the topology of active sites: on the prediction of pockets and subpockets,” Journal of Chemical Information and Modeling, vol. 50, no. 11, pp. 2041–2052, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. G. B. McGaughey, M. Gagné, and A. K. Rappé, “π-Stacking interactions. Alive and well in proteins,” The Journal of Biological Chemistry, vol. 273, no. 25, pp. 15458–15463, 1998. View at Publisher · View at Google Scholar · View at Scopus